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ABSTRACT 
Objective: The Objective of present work is method development and validation of HPLC method for the quantitation of Ramipril in Fast dissolving 
tablet (FDT).  
Methods: A stable, linear, rapid, accurate and selective HPLC method has been developed for the quantification of Ramipril in FDT using buffer and 
acetonitrile: methanol (60:40 v/v) ratio in combination as mobile phase and at the flow rate of 1 ml/minute at λmax 210 nm. Chromatographic 
separation was performed on Shimadzu SPD-20A, SD-M10 AVP-Shimadzu, an ODS C-18 Kromacil (250 mm × 4.60 mm) column used as stationary 
phase. The quantitation of Ramipril done by HPLC, parameters studied were retention time, linearity, accuracy, precision, detection limit, 
quantitation limit and stability. 
Results: Linear regression analysis data show a good linear relationship between response and concentration in the range of 5-30 µg/ml; detection 
carried out at λmax210 nm; the linear regression equation for Ramipril was Y=10327x+72877; R²=0.998. The retention time of the Ramipril was 
2.910 min. Percent recoveries obtained for Ramipril was 99.58-100.15%. LOD and LOQ value was 0.802µg/ml and 1.4µg/ml for Ramipril 
respectively.  
Conclusion: The result suggested that proposed method gives good peak resolution of Ramipril within short analysis time (<10 min) and high 
percentages of the recovery shown that method is free from interference of excipient present in the formulation. The % RSD of each parameter lies 
below the limit of 2%, proven the suitability. The statistical analysis proved that the proposed method is precise, accurate, selective and rapid for 
the HPLC estimation of Ramipril. 
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INTRODUCTION 
Fast dissolving tablets (FDT) have more advantage for pediatric, geriatric 
[1-2], bedridden, disabled patients and also for those have difficulty in 
swallowing conventional tablets, capsules and liquid orals. FDT are the 
tablets which will rapidly disintegrate in the mouth without the need of 
water [3]. Pre gastric absorption of FDT can result in improved 
bioavailability and as a result of reduced dose [4]. Ramipril (fig. 1) is (2S, 
3aS, 6aS)-1-[(S)-2-[[(S)-1-(ethoxy-carbonyl)-3-phenylpropyl]-amino]-
propanoyl]-octahydrocyclopenta-pyrrole-2-carboxylic acid. Ramipril 
is indicated for the treatment of mild to moderate hypertension [5], 
congestive heart failure, myocardial infarction in patients with 
clinical evidence of heart failure [6]. Ramipril, a prodrug, is 
converted to the active metabolite ramiprilat by liver esterase 
enzymes [7]. However, it may cause hypotension, cough and other 
side effect [8]. The extensive literature survey has revealed that 
various methods was used for estimation of Ramipril by HPLC [9-
12], HPTLC [13], Spectrophotometer [14], LC [15], LC-MS (Liquid 
chromatography-mass spectrophotometry) [16], Atomic-absorption 
spectrometry [17-18], and Capillary electrophoresis [19] has been 
reported earlier.  
FDT of Ramipril was previously prepared [20]. The aim of the 
present work is method development and validation of prepared 
FDT of Ramipril by HPLC method. 
MATERIALS AND METHODS 
Chemicals and reagent 
HPLC grade methanol and acetonitrile were procured from Sigma 
Aldrich, India. Sodium acetate (CAS No. 6131-90-4) and ammonium 
acetate (CAS No. 631-61-8) was procured from Chemical Drug 
House, New Delhi, India. HPLC grade water was obtained from Milli-
Q system. Gift sample of Ramipril procured from Alkam 
Pharmaceutical Ltd, Baddi, India. 
Apparatus and chromatographic condition 
Chromatographic separation was performed on Shimadzu SPD-20A, 
SD-M10 AVP-Shimadzu, UV/Vis Diode Array Detector with ODS C18 
Kromacil (250 mm × 4.60 mm). The elution was carried out 











Fig. 1: Chemical structure of ramipril 
 
Mobile phase selection 
An optimized chromatogram is the one in which all the peaks are 
symmetrical and are well separated in less run time. The mobile 
phase was selected on the basis of best separation, peak purity 
index, peak symmetry, theoretical plate etc. The standard 
solution of Ramipril was run and combination of solvent have 
been tried to get a symmetry and stable peak (each mobile phase 
was filtered & degassed by solution through 0.45µ membrane 
filter to remove particulate matter) mobile phase selection for 
HPLC analysis are shown in table 1. Flow rate employed for 
analysis was 1.0 ml/min. 
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Table 1: Mobile phase selection for HPLC analysis 
S. No. Mobile phase Flow rate Ratio Retention time Suitable 
1 methanol: acetonitrile 1.0 ml/min 80:20 - not 
2 methanol: acetonitrile 1.0 ml/min 70:30 - not 
3 (methanol: acetonitrile 70:30): acetate buffer 1.0 ml/min 50:50 8.910 Less suitable 
4 (methanol: acetonitrile; 70:30): acetate buffer 1.0 ml/min 60:40 2.910 Suitable 
 
Preparation of mobile phase 
The mobile phase was prepared by mixing of methanol and 
acetonitrile in the ratio 70:30 (%v/v), the solution was filtered, this 
solution called mobile phase-A and dissolved 136 gm of sodium 
acetate and 77 gm of ammonium acetate in distilled water and dilute 
with distilled water to 1000 ml. Then add 250 ml of glacial acetic 
acid and mix, this solution called mobile phase-B. The final mobile 
phase was prepared by mixing both mobile phase A and B in the 
ratio of 60:40 (%v/v). 100 mg of Ramipril was weighed accurately 
and transferred to a 100 ml volumetric flask and volume was 
adjusted to the mark with the mobile phase in the ratio of 60:40 
(%v/v), (1000 µg/ml). From the above solution 1 ml was 
transferred to 10 ml volumetric flask, and make up the volume up to 
mark with mobile phase to get the concentration of 100µg/ml. Then 
take 2 ml form the above solution and volume make up to the mark 
with mobile phase to get the concentration of 20µg/ml. Resulting 
solution was scanned over UV range (200-400 nm), maximum 
absorbance was found at λmax 210 nm. 
Preparation of standard stock solution 
10 mg of Ramipril was weighed accurately and transferred to 10 ml 
volumetric flask and then volume was adjusted to the mark with the 
mobile phase, to give a stock solution of 1000 µg/ml. From stock 
solution of Ramipril 1 ml was taken and diluted up to 10 ml with the 
mobile phase, to give a stock solution 100 µg/ml. From this solution 
0.5, 1.0, 1.5, 2.0, 2.5, 3.0 ml solution was transferred to 10 ml 
volumetric flask and make up the volume up to 10 ml with mobile 
phase gives standard drug solution concentration ranges of 5, 10, 15, 
20, 25, 30 µg/ml. Each of the standard drug solution was injected 3 
times and the mean peak area of drug was calculated and plotted 
against the concentration of the drug. The regression equation was 
found out by using this curve. Mean AUC recorded for all the 
concentration range and typical calibration curve was shown in fig. 2. 
 
Fig. 2: Calibration curve of ramipril by HPLC (λmax210 nm) 
 
Analysis of FDT of ramipril (F4) 
Twenty tablets were weighted individually from optimized 
formulation F4 (FDT of Ramipril) and powdered. Weight equivalent 
to 100 mg of Ramipril was transferred to 100 ml volumetric flask 
and dissolve in mobile phase. The solution was shaking vigorously 
for 10 min and filtered through 0.45 µ membrane filter paper and 
then volume make up to the mark with mobile phase to get a 
solution containing concentration 1000 µg/ml.  
From the above solution 1 ml of solution was taken and diluted to 10 
ml with mobile phase to get a solution containing 100µg/ml. From 
the above solution 1 ml of solution was taken and diluted to 10 ml 
with mobile phase to get a solution containing 10 µg/ml 
concentration of Ramipril. The amount of Ramipril per tablets was 
calculated by extrapolating the value of peak area from the 
calibration curve. Analysis procedure was repeated six times with 
tablet formulation shown in table 2. 
 
Table 2: Analysis of FDT of ramipril (F4) 
S. No. Actual amount (mg/tab) Peak area Amount found (mg/tab) % Amount found 
1 20 1366565 20.05 100.4 
2 20 1366555 19.97 99.4 
3 20 1366565 19.90 99.60 
4 20 1366656 19.91 99.70 
5 20 1366541 19.95 99.75 
6 20 1366532 20.01 100.01 
  Mean 1366569 19.99 99.81 
  SD 44.609 0.0578 0.350 
 %RSD 0.0032 0.2891 0.3506 
n=6; F4 optimized formulation for analysis; RS. Denotes for relative standard deviation; SD. denotes for standard deviation. 
 
Table 3: Linearity 
Parameter Ramipril 
λmax (nm) 210 
Beer’s law limit (µg/ml) 5-30 
Regression equation (y =mx+c) Y=10327x+72877 
Slope (m) 10317 
Intercept (c) 72877 
Correlation coefficient (R2) 0.998 
LOD 0.802 µg/ml 
LOQ 1.4 µg/ml 
n=3; LOD denoted for limit of detection; LOQ denote for limit of quantization; maximum absorbance 210 nm. Concentration range 5-30 µg/ml 
Kashaw et al. 




The linearity of the method was determined by analyze several 
aliquots of Ramipril in concentrations range of 5-30 µg/ml, repeated 
three times. Linearity was observed in the final concentration range 
of 5-30 µg/ml; with the correlation coefficient of 0.998 for Ramipril. 
Calibration curve was plotted using AUC versus concentration of 
standard solution. Peak area recorded for all the peaks was given in 
table 3. The slope and intercept value in calibration curve of 
Ramipril was Y=10327x+72877; R²=0.998. The result shows an 
excellent correlation exists between peak area and concentration of 
the drugs within the concentration range 5-30 µg/ml. 
Assay 
20 µl of standard and sample solution were injected into injector of 
the liquid chromatogram, form the peak area of Ramipril, amount of 
drug in sample were computed.  
Method validation 
Validation of the method was done according to ICH guidelines [21] 
by Simultaneous equation method. 
Accuracy 
The accuracy of the method was determined by recovery study using 
the standard addition method. Pre analyzed samples were spiked 
with standard drug (Ramipril) at three different concentration 
levels, i.e., 80, 100 and 120%, and the mixtures were reanalyzed by 
the proposed method. Each level was repeated for three times. Data 
obtained was analyzed for percent recovery. Standard dilutions 
were prepared and three replicates of each dilution were analyzed 
in same day for repeatability and result was subjected to statistical 
analysis.  
Precision 
The precision of the method was carried out by intermediate 
precision. In intermediate precision, day to day precisions and 
analyst to analyst precision were performed. Day to day precisions 
and analyst to analyst precision were performed by preparing and 
applying concentrations; 25 µg/ml of Ramipril in day 1 & day 2 and 
Analyst 1 & Analyst 2 respectively. Assay for each analysis was 
calculated and mean, S. D., % RSD was determined. 
Limit of detection and limit of quantification 
Limit of Detection (LOD) and Limit of Quantification (LOQ) of the 
developed method were determined by injecting progressively low 
concentration of the standard solution using the developed HPLC 
method. The LOD is the smallest concentration of the analyte that 
gives a measurable response (signal to noise ratio 3). The LOQ is the 
smallest concentration of the analyte which gives response that can 
be accurately quantified (signal to noise ratio 10). LOD and LOQ 
value measured by the following formula;  
The LOD = 3.3σ/S and LOQ = 10σ/S; 
Where σ = Standard deviation of the response; S = Slope of the 
deviation curve. In order to demonstrate the stability of both 
standard and sample solution during analysis, both solutions were 
analyzed over a period of 5 h at room temperature. 
Ruggedness and robustness 
The Ruggedness of the method was determined by carrying out the 
experiment on different instrument like Shimadzu SPD-20A and 
Agilent HPLC by different operator using different columns of 
similar type like Hypersil C18, Intersile C18. The Robustness of the 
method was determined by making slight changes in the 
chromatographic condition. As per ICH guidelines, small but 
deliberate variations in concentration of the mobile phase were 
made to check the method. Mobile phase varies methanol: acetonitrile 
(80:20)), (methanol: acetonitrile (70:30)), (methanol: acetonitrile, 
(70:30): acetate buffer {50:50}; (methanol: acetonitrile, (70:30): acetate 
buffer {60:40} ratio and flow rate varies 0.5-1.5 ml/min. 
Solution stability 
In order to demonstrate the stability of both standard and sample 
solution during analysis, both solutions were analyzed over a period 
of 5 h at room temperature. 
RESULT AND DISCUSSION 
Accuracy 
The accuracy of the method was determined by recovery studies by 
standard addition method according to ICH guidelines. The pre-
analyzed samples were spiked with standard drug Ramipril at three 
different concentration levels, i.e., 80%, 100% and 120%. The 
mixtures were reanalyzed by the proposed method and found to be 
within the limit of 99.856-100.008% for Ramipril. The values of 
percent recovery are listed in table 4. The % RSD below than 2, 
states that method is accurate. So the method can be used for the 
estimation of Ramipril from its tablet dosage form, were found more 
accurate without any interference.  
 
Fig. 3: Retention time of ramipril by HPLC method 
  
Table 4: Drug recovery study of ramipril 
Description 80 100 120 




































% Mean Recovery 100.008 99.900 99.856 
SD* (n=3) 0.137689 0.100 0.2542 
%RSD 0.133 0.100 0.254 
n=3, RSD denotes for relative standard deviation; SD denotes for standard deviation. 
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The HPLC procedure was optimized with a view to develop accurate 
and stable assay method. The drugs Ramipril was run in mobile 
phase composition with different ODS C18 columns (Kromacil; 250 
mm ×4.60 mm). The flow rate was maintained at 1 ml/min with 
temperature at 44ºC; detection at 210 nm gave sharp and 
symmetrical peak with retention time 2.910 min of Ramipril. The 
typical chromatogram of the Ramipril was shown in fig. 3. 
Precision 
The precision of the method was carried out by intermediate 
precision. In intermediate precision, day to day precisions and 
analyst to analyst precision were performed. 25µg/ml concentration 
was used for Ramipril. In day to day precision, for Ramipril % R. S. D. 
were found to be 0.583 and 0.567 at day 1 and day 2 respectively. In 
analyst to analyst precision for Ramipril % R. S. D. were found to be 
0.854 and 0.654 at analyst 1 and analyst 2 respectively. Assay for 
each analysis was calculated and mean, S. D., % RSD was determined 
and data presented in table 5. The % R. S. D value for day to day 
precision and analyst to analyst was below than 2, as according to 
the ICH guidelines. These results were states that validation method 
was precise. 
Limit of detection and limit of quantification 
The LOD and LOQ for Ramipril were found to be 0.802µg/ml and 
1.4µg/ml respectively. The LOD and LOQ value for Ramipril was below 
than 2, conclude that developed method is detected and quantify the 
drug in small quantity in dosages form (table 3). The retention time of 
Ramipril was 2.910 min. shown in fig. 3 and peak area of Ramipril 
remained almost unchanged (% RSD was less than 2.0) and there was 
no significant degradation found in indicated period, for at least 5 h 
which was sufficient to complete the whole analytical process. 
Ruggedness 
The Ruggedness of the method was determined by carrying out the 
experiment on different instrument like Shimadzu SPD-20A and 
Agilent HPLC by different operator using different columns of 
similar type like Hypersil C18, Intersile C18. The robustness of the 
method was determined by making slight changes in the 
chromatographic condition. These variations did not cause any 
significant difference in resolution of HPLC method, represent its 
robustness. The flow rate varies from 0.5-1.5 ml/min does not cause 
any variation in the chromatogram. 
 
Table 5: Precision 
(A) Intermediate precision: day-to-day 
Ramipril  Day-1 Day-2 
Concentration (µg/ml) Peak area Retention time (min.) Peak area Retention time (min.) 
25 2561347 2.35 2585958 2.32 
25 2582789 2.32 2572418 2.36 
25 2525958 2.36 2539921 2.34 
25 2569921 2.34 2561347 2.35 
25 2572418 2.35 2521347 2.34 
25 2535958 2.34 2582789 2.34 
Mean 2558065 2.343 2560630 2.341 
SD 22307.85 0.0136 25471.62 0.0132 
%RSD 0.87206 0.58304 0.99474 0.56763 
 
(B) Intermediate precision: analyst-to analyst 
Ramipril Analyst-1 Analyst-2 
Concentration 
(µg/ml) 
Peak area Retention time 
(min.) 
Peak area Retention time (min.) 
25 2595958 2.32 2561347 2.35 
25 2572418 2.36 2582789 2.32 
25 2569921 2.34 2542431 2.33 
Mean 2579432 2.34 2562189 2.333 
SD 14366 0.02 20192.17 0.015 
%RSD 0.55694 0.8547 0.78808 0.6547 
n=5; for day to day precision; n=3; for analyst to analyst precision; RSD denotes for relative standard deviation; SD. Denotes for standard deviation. 
 
Solution stability 
The retention time of ramipril was 2.910 min. shown in fig. 3 and 
peak area of ramipril was remained almost unchanged (% R. S. D. 
was less than 2.0) and there was no significant degradation found in 
indicated period, for at least 5 h which was sufficient to complete the 
whole analytical process. 
Recovery studies 
To study the accuracy and reproducibility of the proposed method 
recovery experiment study were carried out. A fixed amount of pre 
analyzed sample taken and standard drug was added at 80%, 100%, 
and 120% level. Each level was repeated for three times. The mean 
recovery of Ramipril was in the range of 99.856%-100.008% (table 4). 
DISCUSSION 
The LOD and LOQ value for the Ramipril obtained, demonstrate the 
suitability of the system for the analysis of the drug; system 
suitability parameter may fall within±2% range during routine 
performance of the method. To study the accuracy and 
reproducibility of the proposed method recovery experiment study 
were carried out, in this a fixed amount of pre analyzed sample 
taken and standard drug was added at 80%, 100%, and 120% level. 
Each level was repeated for three times. The mean recovery of 
Ramipril was in the range of 99.856%-100.008%. Recovery data 
states that the proposed method is accurate and reproducible. The 
lower value of the % RSD of assay indicates that the method is 
accurate. These results concluded that the proposed method is 
better in comparison to previously reported method.  
In present method retention time of the Ramipril is 2.910 min is 
least as compare to other method reported by Kurade et al., 2009; 
Rao et al., 2010; Sharma et al., 2012;Kumari et al., 2014, that state 
the retention time (run time) of Ramipril is 3.68 min, 3.30 min, 
3.620 min & 4.003 min respectively [22-24]. This shown that the run 
time of Ramipril is less than previous reported method. The LOD & 
LOQ value of Ramipril is 0.802µg/ml and 1.4µg/ml respectively, is 
Kashaw et al. 
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better than previously reported by Kumari et al., 2014 was 1.2µg/ml 
and 4.9µg/ml respectively; but Yadav et al., 2012 was states that the 
LOD and LOQ value of Ramipril is 0.5µg/ml and 1.0µg/ml 
respectively [25]. This shown that the less sample is required for the 
quantitation and quantification of the drug. Accuracy and percent 
recovery of Ramipril is 99-100% better than reported by Yadav et 
al., 2012, that state the percent recovery 98.00%. These data 
represent that this method is better than existing method and have 
less runtime compared to the previously reported method. 
CONCLUSION 
The proposed method gives good peak resolution of Ramipril within 
short analysis time (<5 min). The method is very simple, rapid. High 
percentages of the recovery show that this method is free from 
interference of excipient present in the formulation. The % RSD of 
each parameter lies below the limit of 2%, as per the ICH guidelines. 
The methods developed were found to be simple, rapid, selective, 
accurate, precise and economical for the estimation of Ramipril in 
solid dosage form. 
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